Mr. Sebaaly also shares insight on Roche's (SIX: RO, ROG; OTCQX: RHHBY) Herceptin® cancer drug.
Interview:
Q: Investorideas.com staff
Can you give investors a brief background on your lead compound , Adva-27a, your proprietary technology behind it and how it targets aggressive forms of cancer?
A: Mr. Camille Sebaaly, CFO
Adva-27a is a small molecule which we designed and synthesized de novo. Patents covering Adva-27a and derivatives have been issued in the United States and Europe and are still pending in other places around the world. Adva-27a was designed it to specifically target multidrug resistant (or aggressive) types of cancer.
Q: Investorideas.com staff
The Company announced findings last week from the cytotoxicity study- can you give us some brief hi-lights and the significance of the results?
A: Mr. Camille Sebaaly, CFO
Last week we announced the results of our most recent studies in which we found that Adva-27a is remarkably capable of killing multidrug resistant small cell lung cancer. Small cell lung cancer is perhaps the most aggressive primary cancer. Sadly, the prognosis for a freshly diagnosed patient with small cell lung cancer is only a few months. As you know, we had announced back in July of last year that Adva-27a also kills multidrug resistant breast cancer cells. Similarly, the prognosis for multidrug resistant breast cancer patients is only a few months. We are delighted at the opportunity to offer both of these patient groups hope through our Adva-27a. As far we know, Adva-27a is the only drug anywhere in the world that can treat these patients.
Q: Investorideas.com staff
Can you discuss briefly the pharmacokinetics studies results announced in May?
A: Mr. Camille Sebaaly, CFO
The pharmacokinetic parameters of Adva-27a which we announced in May were excellent. Adva-27a has all the properties of a good pharmaceutical. For example, it reaches a very high initial plasma concentration, which means it starts working fast, and has an intermediates plasma half-life implying that it does not linger in the blood stream to cause severe side-effects and other complications.
Q: Investorideas.com staff
Can you give investors insight into the type of cancer Herceptin®, a drug marketed by Roche (SIX: RO, ROG; OTCQX: RHHBY) (the world's largest biotech company) targets and where you see Sunshine Biopharma filling the gap?
A: Mr. Camille Sebaaly, CFO
Herceptin® is an excellent drug and is very effective in treating Her2-Positive breast cancer patients. However, only about 25% of the breast cancer patients are Her2-Positive. For the remaining 75%, Herceptin® does not work. This is where our Adva-27a comes in. It is interesting to note that Herceptin® sales are in excess of $5 billion a year.
About Sunshine Biopharma Inc. (OTCBB: SBFM)
www.sunshinebiopharma.com
SBFM Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, including biotech and pharma stocks. Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and biotech stock alerts
Research biotech stocks at the Investor Ideas Biotech stocks Directory
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26 th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com
Published at Investorideas.com newswire
Learn more about Sunshine Biopharma Inc. (OTCBB:SBFM): ProfileDisclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensates Investorideas.com for news release publishing and distribution : one hundred thousand 144 shares for three months starting June 26th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
1 comment:
The reputation of Forex trading is improving high these days. It is one of the preferred preferences for people who're looking for solutions to make quick cash.
Trading signals
Post a Comment